Abecma® (idecabtagene vicleucel) – Expanded indication
April 5, 2024 - Bristol Myers Squibb and 2seventy bio announced the FDA approval of Abecma (idecabtagene vicleucel), for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.